Ripple Therapeutics Announces New Vice President, Operations

TORONTO, ON, CANADA / APRIL 11, 2022 - Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel therapeutics, is pleased to announce the addition of Fraidianie Sévigné, to the leadership team as Vice President, Operations.

Fraidianie brings over 20 years of pharmaceutical industry experience, serving in senior leadership roles encompassing Operations, Quality, Compliance, and Regulatory Strategy. She has contributed to the successful launch of over 130 products, at various stages of development, from clinical evaluations to management of manufacturing scale-up and validation through to commercialization and quality operations for Canadian, U.S. and International markets.


“We are very pleased to welcome Fraidianie to Ripple as VP Operations and a member of our leadership team”, stated Tom Reeves, President and CEO, Ripple Therapeutics.  “Her vast experience in both start-up and mature pharmaceutical organizations in Operations, Quality and Regulatory Compliance will be a great complement to our existing team.  And her results-oriented leadership style and history of innovation and creativity will fit well with the Ripple culture.”


About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development. www.rippletherapeutics.com

 

 

Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

 

RIPPLE-ABBVIE OPHTHALMIC DRUG DELIVERY PANEL

February 12, 2026
Our Chief Technology Officer, Wendy Naimark , was pleased to be speaking with AbbVie Directors, Allison Hoch, PhD, MBA, Director of Global Alliances and Amy Hopkin Director of Search & Evaluation for AbbVie Eyecare, on a Harnessing Innovation & Collaboration to Accelerate Ophthalmic Drug Delivery Panel at the 4th Annual Ophthalmic Drug Delivery Summit on Thursday January 29th in San Francisco, CA. 🗣️ Topic: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact. Areas Covered: ✅ Co-developing platforms, managing device timelines and regulatory alignment in combo products ✅ Leveraging the speed and innovation of biotech startups with deep experience and resources of pharma ✅ Continuous learning through cooperation during diligence, development planning and execution phases ✅ The importance of proactive, transparent communication across functions to anticipate challenges and optimize for success View Presentation

Ripple Therapeutics Enters Collaboration with Bausch + Lomb

November 25, 2025
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.